Adverum publishes macular degeneration med data

Adverum Biotechnologies announced the publication of preclinical long-term expression and efficacy data in “Molecular Therapy”, the international journal for research on the development of molecular and cellular therapeutics to correct genetic and acquired diseases. A single intravitreal administration of ADVM-022 in non-human primates, or NHPs, provided stable and robust intraocular expression of aflibercept and resulted in high levels of aflibercept within the retina and choroid where wet age-related macular degeneration occurs. Robust aflibercept expression in retinal and choroidal tissues obtained at 16 months post-administration demonstrated that cells transduced with ADVM-022 may continue to generate aflibercept for an extended period of time. In a laser-induced choroidal neovascularization model in NHPs, a single intravitreal administration of ADVM-022 13 months before lasering prevented the occurrence of clinically relevant choroidal neovascularization lesions, similar to animals that received a bolus of intravitreal aflibercept at the time of lesioning. A single intravitreal administration of ADVM-022 may provide a safe and effective long-term treatment option for wet AMD.
https://thefly.com/landingPageNews.php?id=2831223